Patents Assigned to Eagle Pharmaceuticals, Inc.
-
Patent number: 9579384Abstract: Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.Type: GrantFiled: August 6, 2015Date of Patent: February 28, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventors: Srikanth Sundaram, Scott L. Tarriff
-
Patent number: 9572888Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: GrantFiled: June 16, 2016Date of Patent: February 21, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 9572887Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: GrantFiled: June 16, 2016Date of Patent: February 21, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 9572796Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: February 2, 2016Date of Patent: February 21, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 9572797Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: February 2, 2016Date of Patent: February 21, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 9265831Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: September 19, 2013Date of Patent: February 23, 2016Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 9144568Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: GrantFiled: May 18, 2015Date of Patent: September 29, 2015Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 9034908Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: GrantFiled: March 15, 2013Date of Patent: May 19, 2015Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 9000021Abstract: Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.Type: GrantFiled: March 15, 2013Date of Patent: April 7, 2015Assignee: Eagle Pharmaceuticals, Inc.Inventors: Srikanth Sundaram, Scott L. Tarriff
-
Publication number: 20140275196Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: ApplicationFiled: December 5, 2013Publication date: September 18, 2014Applicant: Eagle Pharmaceuticals, Inc.Inventor: Srikanth Sundaram
-
Publication number: 20140094496Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicant: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Publication number: 20140024691Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: September 19, 2013Publication date: January 23, 2014Applicant: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 8609707Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: January 28, 2011Date of Patent: December 17, 2013Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20130253025Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Publication number: 20130253026Abstract: Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: EAGLE PHARMACEUTICALS, INC.Inventors: Srikanth Sundaram, Scott L. Tarriff
-
Publication number: 20130231357Abstract: Long term storage stable pemetrexed-containing liquid pharmaceutical compositions are disclosed. The compositions can include pemetrexed or pharmaceutically acceptable salts thereof; an antioxidant selected from lipoic acid, dihydrolipoic acid, methionine and mixtures thereof; a chelating agent selected from lactobionic acid, sodium citrate, tribasic and mixtures thereof; and a pharmaceutically acceptable fluid. The pH of the compositions is in a range of about 8 to about 9.5. The pemetrexed-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 227 nm, after at least about 18 months of storage at a temperature of from about 5° C. to about 25° C. Methods of preparing the formulation as well as methods of treatment of pemetrexed-susceptible diseases using the same are also disclosed.Type: ApplicationFiled: July 26, 2011Publication date: September 5, 2013Applicant: EAGLE PHARMACEUTICALS, INC.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20130210879Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid contains a mixture of PEG and PG; an organic or inorganic compound in an amount sufficient to obtain a pH of from about 6.0 to about 11 for the polyethylene glycol, as measured using USP monograph for polyethylene glycol; and optionally an antioxidant. The bendamustine-containing compositions have less than about 5% total esters, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Applicant: EAGLE PHARMACEUTICALS, INC.Inventor: Eagle Pharmaceuticals, Inc.
-
Patent number: 8431539Abstract: Long term storage stable daptomycin-containing compositions are disclosed. The compositions include daptomycin or a pharmaceutically acceptable salt thereof at a concentration of less than or equal to about 25 mg/mL, a buffer having an acidic functional group and have a pH of from about 6.0 to about 7. The formulations are surprisingly free of degradation products such as the hydrolysis product of daptomycin and the ?-isomer of daptomycin after storage periods of at least about 18 months.Type: GrantFiled: September 17, 2010Date of Patent: April 30, 2013Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Bulusu Bhanu Teja
-
Publication number: 20130023559Abstract: An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-use 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicant: EAGLE PHARMACEUTICALS, INC.Inventor: Nageswara R. PALEPU
-
Patent number: D676572Type: GrantFiled: October 3, 2011Date of Patent: February 19, 2013Assignee: Eagle Pharmaceuticals, Inc.Inventor: Scott L. Tarriff